OR WAIT null SECS
June 10, 2022
Case report details diagnosis based on imaging diagnostics.
June 08, 2022
Embracing this new model of care can allow optometric practices to flourish—and may enable earlier detection of conversion from intermediate dry to wet AMD.
June 07, 2022
Early diagnosis and intervention are crucial when managing this patient base.
June 02, 2022
All data were collected in the Fight Retinal Blindness! Registry.
June 01, 2022
This is the second FDA-approved indication for BEOVU; it was initially approved in 2019 for the treatment of wet AMD.
A decision by the FDA is expected in August 2022.
May 30, 2022
The ADA now recommends an individualized approach at diagnosis of diabetes as well as for adults who do not have symptoms to be screened at age 35 years.
May 18, 2022
Four patients present with previously undiagnosed conditions.
May 17, 2022
The company, formerly known as Clover Therapeutics, intends to use the funding to advance two lead drug candidates that target molecularly-defined AMD patient subtypes.
May 12, 2022
The company's technology allows for ECPs to detect, monitor, and treat AMD 3 years before clinical diagnosis.
Report: ortho-K expected to surge over next 2 years
Impact of vision impairment on children’s mental health
First patient dosed in phase 1 study of IBI324 for DME
Study: Neurolenses significantly impact reading speed
